168 related articles for article (PubMed ID: 12068388)
1. Therapeutic options in the management of renal cell carcinoma.
Glaspy JA
Semin Oncol; 2002 Jun; 29(3 Suppl 7):41-6. PubMed ID: 12068388
[TBL] [Abstract][Full Text] [Related]
2. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
4. Histamine as an adjunct to immunotherapy.
Naredi P
Semin Oncol; 2002 Jun; 29(3 Suppl 7):31-4. PubMed ID: 12068386
[TBL] [Abstract][Full Text] [Related]
5. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).
Merad M; Angevin E; Wolfers J; Flament C; Lorenzi I; Triebel F; Escudier B; Zitvogel L
J Immunother; 2000; 23(3):369-78. PubMed ID: 10838666
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
7. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
8. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
[TBL] [Abstract][Full Text] [Related]
9. Interferons and interleukins in metastatic renal cell carcinoma.
Choudhury M; Efros M; Mittelman A
Urology; 1993 Jan; 41(1 Suppl):67-72. PubMed ID: 7678365
[TBL] [Abstract][Full Text] [Related]
10. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
Hutson TE; Quinn DI
Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
[TBL] [Abstract][Full Text] [Related]
11. Histamine in cancer immunotherapy: a preclinical background.
Hellstrand K
Semin Oncol; 2002 Jun; 29(3 Suppl 7):35-40. PubMed ID: 12068387
[TBL] [Abstract][Full Text] [Related]
12. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma.
Mickisch GH
Eur Urol; 2003 Jun; 43(6):670-9. PubMed ID: 12767369
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
[TBL] [Abstract][Full Text] [Related]
15. Interferon in metastatic renal cell carcinoma.
Fosså SD
Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.
Sella A; Kilbourn RG; Gray I; Finn L; Zukiwski AA; Ellerhorst J; Amato RJ; Logothetis CJ
Cancer Biother; 1994; 9(2):103-11. PubMed ID: 7812360
[TBL] [Abstract][Full Text] [Related]
17. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
18. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2.
Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy in the management of metastatic renal carcinoma].
Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA
Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458
[TBL] [Abstract][Full Text] [Related]
20. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]